Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Eric Matteson

Rheumatology Rochester, MN Medical Doctor

NPI 1982677563 CMS profile 1245007

200 1St St Sw, Rochester, MN 55905

Open in the dashboard

General payments

$51,450

58 records reported · program years 2019–2025

Research payments

$7,859

Paid to them · 2 records reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$1,105 paid to institutions, not to them · program year 2021

Through program year 2025, Eric Matteson of Rochester, MN is reported in the CMS Open Payments database as having received $51,450 across 58 general payments and $7,859 in research payments paid to them. Separately, studies naming them as principal investigator received $1,105 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 90th percentile of Rheumatology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

8 rows
Year Kind Relative to this record's peak year Amount Records
2025 Research $2,067 1
2024 General $5,659 1
2024 Research $5,792 1
2023 General $8,346 7
2022 General $1,350 3
2021 General $11,878 14
2020 General $11,697 13
2019 General $12,520 20

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Eric Matteson
  • Rheumatology median
  • Middle half of Rheumatology
  • National median

In program year 2025, general payments to Eric Matteson were reported at $0. Among 4,454 Rheumatology profiles paid that year, the median was $903 and the middle half received between $171 and $2,775.

Show as a table
Year Eric Matteson Rheumatology median Middle half National median
2019 $12,520 $744 $153–$2,687 $163
2020 $11,697 $462 $98–$2,027 $114
2021 $11,878 $531 $101–$2,153 $132
2022 $1,350 $627 $125–$2,303 $149
2023 $8,346 $741 $145–$2,524 $160
2024 $5,659 $830 $166–$2,660 $164
2025 $0 $903 $171–$2,775 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Boehringer Ingelheim International GmbH $24,993 30 payments
  2. Gilead Sciences, Inc. $11,852 18 payments
  3. Boehringer Ingelheim Pharmaceuticals, Inc. $7,678 5 payments
  4. Boehringer Ingelheim Hong Kong Ltd $2,000 1 payment
  5. Boehringer Ingelheim Do Brasil Quimica e Farmaceutical Ltda. $1,875 1 payment
  6. Boehringer Ingelheim Taiwan Ltd. $1,594 1 payment
  7. Horizon Therapeutics plc $1,458 2 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $27,865 29 payments
  2. Consulting Fee $21,603 13 payments
  3. Travel and Lodging $1,558 5 payments
  4. Food and Beverage $424 11 payments
Products named General payments · program years 2019–2025
  1. OFEV Respiratory $28,099 26 payments
  2. OFEV Respiratory $9,373 10 payments
  3. OFEV Oncology $669 2 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Research payments came from Research payments · program years 2019–2025
  1. Amgen Inc. $7,859 2 payments

Records

60 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record